In a recent study, the Syk inhibitor fostamatinib prevented skin and lung fibrosis and inflammation in bleomycin-induced systemic scleroderma mice, and the anti-fibrotic effects of fostamatinib were associated with decreased Syk phosphorylation and TGF-β expression (31). Here, TGFB1 is linked to systemic sclerosis.